Hologic, Inc. (NASDAQ:HOLX) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Hologic, Inc. has received an **average rating of "Moderate Buy"** from 17 brokerages, with 8 analysts assigning a buy rating and 1 giving a strong buy rating.
• The average **twelve-month target price** for Hologic's stock among analysts is **$79.38**, with recent price objectives ranging from $68 to $87.
• Hologic's recent earnings report showed **$1.08 earnings per share**, exceeding estimates, and a year-over-year revenue increase of **1.2%**, reflecting solid financial performance.

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) has received an average recommendation of "Moderate Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $79.3846.

A number of equities research analysts have recently weighed in on HOLX shares. Royal Bank Of Canada upgraded shares of Hologic from a "sector perform" rating to an "outperform" rating and boosted their price objective for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Stephens restated an "overweight" rating and issued a $78.00 price objective on shares of Hologic in a report on Thursday, September 18th. Mizuho set a $75.00 price objective on shares of Hologic in a report on Thursday, July 31st. Morgan Stanley boosted their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Finally, Evercore ISI boosted their price objective on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a report on Tuesday, July 8th.

Institutional Investors Weigh In On Hologic

A number of hedge funds have recently made changes to their positions in HOLX. Capital Investment Counsel Inc increased its stake in shares of Hologic by 2.6% in the second quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider's stock worth $379,000 after buying an additional 150 shares during the period. Greenleaf Trust increased its stake in shares of Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock worth $233,000 after buying an additional 173 shares during the period. Beverly Hills Private Wealth LLC increased its stake in shares of Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares during the period. Schroder Investment Management Group increased its stake in shares of Hologic by 1.4% in the second quarter. Schroder Investment Management Group now owns 15,758 shares of the medical equipment provider's stock worth $1,027,000 after buying an additional 210 shares during the period. Finally, Allworth Financial LP increased its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Up 1.4%

Shares of Hologic stock opened at $67.29 on Tuesday. Hologic has a 1 year low of $51.90 and a 1 year high of $84.39. The firm has a market cap of $14.97 billion, a PE ratio of 27.92, a PEG ratio of 2.40 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. The company has a 50 day simple moving average of $66.53 and a two-hundred day simple moving average of $62.77.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business posted $1.06 earnings per share. Hologic's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts expect that Hologic will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.